(Q38122640)

29 August 2017

Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? (English)

1 reference

29 August 2017

1 reference

Jean-Louis Montastruc

3

object named as

Jean-Louis Montastruc

0 references

author name string

Jean-Luc Faillie

1

1 reference

29 August 2017

Pierre Petit

2

1 reference

29 August 2017

Dominique Hillaire-Buys

4

1 reference

29 August 2017

20 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

36

1 reference

29 August 2017

693-707

1 reference

29 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-013-0086-y

29 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

PPARgamma-independent antitumor effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Diabetes mellitus and risk of bladder cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Diabetes and risk of bladder cancer: evidence from a case-control study in New England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Effect of rifampicin on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and bladder cancer: a propensity score matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0086-Y

Pioglitazone and bladder cancer

21 January 2018

1 reference

12 December 2020

Meta-analysis confirms raised risk of bladder cancer from pioglitazone

1 reference

12 December 2020

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

1 reference

12 December 2020

1 reference

12 December 2020

Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone

1 reference

12 December 2020

Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

1 reference

12 December 2020

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

1 reference

12 December 2020

10.1007/S40264-013-0086-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference